George L. Sing - 08 Feb 2024 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
Director
Signature
/s/**George L. Sing
Issuer symbol
REGN
Transactions as of
08 Feb 2024
Net transactions value
-$536,670
Form type
4
Filing time
12 Feb 2024, 16:02:31 UTC
Previous filing
04 Jan 2024
Next filing
26 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $206,665 +500 +1.9% $413.33 26,849 08 Feb 2024 Direct
transaction REGN Common Stock Sale $472,500 -500 -1.9% $945.00 26,349 08 Feb 2024 Direct
transaction REGN Common Stock Options Exercise $206,665 +500 +1.9% $413.33 26,849 09 Feb 2024 Direct
transaction REGN Common Stock Sale $477,500 -500 -1.9% $955.00 26,349 09 Feb 2024 Direct
holding REGN Common Stock 750 08 Feb 2024 by Spouse
holding REGN Common Stock 400 08 Feb 2024 by Spouse/Cust Son
holding REGN Common Stock 1,000 08 Feb 2024 by Trust for Son

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -500 -4.6% $0.000000 10,338 08 Feb 2024 Common Stock 500 $413.33 Direct F1
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -500 -4.8% $0.000000 9,838 09 Feb 2024 Common Stock 500 $413.33 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.